Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | How the MPN field has evolved over the years: novel agents, trials, and more

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, comments on how the field of myeloproliferative neoplasms (MPNs) has evolved over the years, emphasizing the growing number of ongoing clinical trials. Dr Mesa comments on novel agents, combination therapies, and the multitude of ongoing research allowing clinicians and researchers to better understand myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.